October agreement advances the U.S. customer program to approximately $5.1 million in committed base services

JERUSALEM, Nov. 5, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today reported financial results for the nine months ended September 30, 2026, and provided a business update. Revenue increased 167% to $2.8 million, compared with $1.05 million in the prior-year period, reflecting the expansion of the Company's CDMO business, including the Yavne operations acquired in February 2026.

 

Corporate Highlights

• Scinai announced an expanded U.S. customer agreement for its wholly owned CDMO subsidiary, Scinai Biopharma Services Ltd. ("SBS"). The agreement, announced in October, includes approximately $5.1 million in committed base service fees, subject to performance and contractual terms, and advances an existing relationship into an integrated clinical manufacturing and chemistry, manufacturing and controls ("CMC") program.
• Committed Customer Orders(1) reached approximately $8.32 million as of November 4, 2026, compared with $1.9 million at year-end 2025, an increase of more than 330%. This operating measure includes authorized work scheduled for 2027 and retains orders already invoiced or recognized as revenue in 2026. It is neither recognized revenue nor remaining unfulfilled backlog.
• October financing transactions generated approximately $5.3 million in combined net proceeds, as previously reported. Together with CDMO customer receipts, these transactions strengthened the Company's liquidity, supporting operating runway to late 2027. Reported bank balances were approximately $8.1 million as of October 27, 2026, compared with cash and cash equivalents of $1.7 million and restricted cash of $195,000 at September 30, 2026. These cash resources are needed, among other things, to support the Company's contractual obligations, including the delivery of committed CDMO customer programs.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.